Liver cancer
Immunomodulating agents:
Immunotherapy treatments may improve the immune system’s ability to combat cancer, but they may not always be viable or accessible for patients with a history of hepatitis infection. As hepatitis infection already compromises the immune system, immunotherapy can place additional stress on healthy liver cells, resulting in their destruction. The following Immunomodulators are used to treat liver cancer:
The drug Nivolumab
Nivolumab is a checkpoint inhibitor that eliminates tumors on the PD-L1/PD-1 pathway, and it can be used in conjunction with ipilimumab to treat advanced liver cancer.
The drug Atezolizumab
Atezolizumab is one of the checkpoint inhibitors that eliminates tumor cells on the PD-L1 pathway and can serve as the initial line of defense for patients with advanced liver cancer.
The drug Ipilimumab
Ipilimumab is one of the checkpoint inhibitors that inhibit the CTLA-4 pathway, and it can be used in conjunction with nivolumab to treat previously treated patients with metastatic liver cancer.
